Cytotoxic drugs: past, present and future Herbie NewellEdward Sausville Introduction 24 December 2015 Pages: 1 - 1
Contemporary reviews on cancer treatment Godefridus J. PetersEric Raymond Introduction 24 December 2015 Pages: 3 - 4
Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy Paola PeregoJacques Robert Review Article 20 November 2015 Pages: 5 - 18
The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Antonio RuggieroDaniela RizzoRiccardo Riccardi Review Article 20 November 2015 Pages: 19 - 26
Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice S. M. AttiaS. F. AhmadS. A. Bakheet Original Article 08 December 2015 Pages: 27 - 33
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma Hiroaki YanagimotoSohei SatoiMasanori Kon Original Article 08 December 2015 Pages: 35 - 41
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human Nigel J. WatersSherri A. SmithRichard Chesworth Original Article 08 December 2015 Pages: 43 - 62
Malformin A1 promotes cell death through induction of apoptosis, necrosis and autophagy in prostate cancer cells Yongqing LiuMing WangHuiqing Yuan Original Article 08 December 2015 Pages: 63 - 75
Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer Angelica L. QuartinoCarina HillenbachBert L. Lum Original Article Open access 08 December 2015 Pages: 77 - 88
Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies Feng JinYuying GaoSrini Ramanathan Original Article 08 December 2015 Pages: 89 - 98
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors Patrick SchöffskiPhilippe AftimosAhmad Awada Original Article 09 December 2015 Pages: 99 - 108
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma S. CeredaM. MilellaM. Reni Original Article 10 December 2015 Pages: 109 - 114
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) Elena MazzaAlba BrandesMichele Reni Original Article 11 December 2015 Pages: 115 - 120
Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study Yusuke TanakaYutaka UedaTadashi Kimura Original Article 11 December 2015 Pages: 121 - 126
Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer Faruk TasSenem KarabulutDerya Duranyildiz Original Article 23 October 2015 Pages: 127 - 131
Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS) Xavier Garcia del MuroEnrique de AlavaJavier Martin-Broto Original Article Open access 12 November 2015 Pages: 133 - 146
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer Taher AL-TweigeriAdher AlSayedGulf Oncology Research Group (GORG-001) Original Article 12 November 2015 Pages: 147 - 153
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70 Taofeek Kunle OwonikokoArif HussainLewis J. Cohen Original Article 14 November 2015 Pages: 155 - 162
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site Dong-Yeop ShinYoon Hee ChoiHye Jin Kang Original Article 20 November 2015 Pages: 163 - 168
A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells Ni ZhenQingyuan YangYongchun Yu Original Article 21 November 2015 Pages: 169 - 180
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells Xin MiaoGilbert KochWilliam J. Jusko Original Article 25 November 2015 Pages: 181 - 193
High CYP2C19 phenotypic variability in gastrointestinal cancer patients K. E. BurnsW.-Y. LoN. A. Helsby Original Article 27 November 2015 Pages: 195 - 204
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis Mariamena ArbitrioMaria Teresa Di MartinoPierosandro Tagliaferri Short Communication 25 November 2015 Pages: 205 - 209
Enhanced brain distribution of carboplatin in a primate model after blood–brain barrier disruption using an implantable ultrasound device Lauriane GoldwirtMichael CanneyAlexandre Carpentier Short Communication 08 December 2015 Pages: 211 - 216
